The Risk of Antipsychotic Drugs on Breast Cancer: A Systematic Review and Meta-analysis

Abstract

Objectives To investigate the association between the consumption of antipsychotic drugs and breast cancer. Methods In this systematic review and meta-analysis study, relevant studies were extracted from different databases including PubMed, ScienceDirect, Cochrane, Medline, and additional sources. The selected studies were statistically analyzed and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Results Of a total of 11 studies selected, five were case-control type and six were cohort type. The overall study quality was 6.7. Meta-analysis of the five case-control studies (which together had 81 766 breast cancer patients and 1 150 316 control participants) showed no significant association between the overall use of antipsychotic drugs and the incidence of breast cancer (odds ratio = 1.06; 95% CI: 0.94–1.19; p = 0.36). Q-test results showed evidence of heterogeneity ( p < 0.10) in the overall analysis. The I 2 statistical assessment also show evidence of heterogeneity (I 2 > 75%). Conclusions The use of antipsychotic drugs does not significantly increase the risk of breast cancer.

An umbrella review of adverse effects associated with antipsychotic medications: the need for complementary study designs

“…Eleven (34%) of the included articles were meta-analyses of observational studies, ( Correll et al, 2022 , Indrakusuma et al, 2022 , Liu et al, 2021 , Mortensen et al, 2020 , Nosè et al, 2015 , Papola et al, 2018 , Seppala et al, 2018 , Vancampfort et al, 2015 , Wang et al, 2021 , Yang et al, 2018 , Zivkovic et al, 2019 ) reporting data on 15 adverse effects and 262 studies, with sample sizes ranging from 11,789 to over 28,000,000 (total N = 38,350,349), which compared exposed to non-exposed individuals. Primary studies were mostly case-control and cohort designs, with some self-controlled case series, cross-over or cross-sectional designs.…”